Clinical Research

The physicians and clinical research coordinators at Capital Allergy & Respiratory Disease Center have a strong commitment to clinical research. We have multiple ongoing clinical trials throughout the year.

If you are interested in participating in one of our studies, please feel free to call or e-mail our clinical research department for further information.

Clinical Research Department
Phone: 916-233-2628
E-Mail: research@capitalallergy.com

You may also submit your name to be considered for a study by filling out this online form

Patients who qualify for participation in these studies will be provided with free study medication, free study-related care, and possible monetary compensation.

Our current studies include:

Immunodeficiency:

  • Hyqvia: Non-interventional post marketing drug study for Primary Immunodeficiency disease (PIDD) for males and females 16 yrs and above on Hyqvia to determine its long term safety and gather additional data in tolerability and adverse events in patients treated with Hyqvia. Patient must be on or prescribed Hyqvia immunoglobulin with no hypersensitivities.

COPD:

  • AIRWISE – A randomized 12 month clinical trial comparing Stiolto Respimat vs triple therapy in the reduction of COPD exacerbations in patients with COPD.

Asthma:

  • CHRONICLE Study – A longitudinal observational study of the characteristics, treatment patterns and health outcomes of individuals with severe asthma in the United States.
  • CAPTAIN Study – A randomized 24-52 week clinical trial comparing the efficacy, safety and tolerability of a triple therapy drug in patients with moderately uncontrolled asthma.
  • QAW039 – A randomized 12-week clinical trial to assess the efficacy and safety of an add-on therapy in adolescents and adults with uncontrolled asthma.